CARISMA TherapeuticsCARM +5.17% EV-to-FCF is 0.08 as of Jul. 03, 2026. The stock has 3 warning signs investors should review. Among 332 Biotechnology companies, CARISMA Therapeutics ranks better than 96.99% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, CARISMA Therapeutics's Enterprise Value is $-1.76 Mil.
CARISMA Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 was $-22.42 Mil. Therefore, CARISMA Therapeutics's EV-to-FCF for today is 0.08.
The historical rank and industry rank for CARISMA Therapeutics's EV-to-FCF or its related term are showing as below:
CARM'
s EV-to-FCF Range Over the Past 10 Years
Min: -13.64 Med: -0.12 Max: 1.41
Current: 0.08
During the past 5 years, the highest EV-to-FCF of CARISMA Therapeutics was 1.41. The lowest was -13.64. And the median was -0.12.
CARM's EV-to-FCF is ranked better than 96.99% of 332
companies
in the Biotechnology industry
Industry Median: 16.26
vs CARM: 0.08
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CARISMA Therapeutics's PE Ratio (TTM) for today is calculated as:
CARISMA Therapeutics's share price for today is $0.0061.
CARISMA Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.200.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CARISMA Therapeutics EV-to-FCF Related Terms
CARISMA Therapeutics EV-to-FCF Historical Data
* Premium members only.
The historical data trend for CARISMA Therapeutics's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, CARISMA Therapeutics's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CARISMA Therapeutics EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CARISMA Therapeutics's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where CARISMA Therapeutics's EV-to-FCF falls into.
CARISMA Therapeutics's current Enterprise Value is $-1.76 Mil.
CARISMA Therapeutics's Free Cash Flow for the trailing twelve months (TTM) ended in Sep. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-22.42 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CARISMA Therapeutics (CARM) has a EV-to-FCF of 0.08 as of Jul. 03, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CARISMA Therapeutics and its competitors. According to the industry distribution chart, CARISMA Therapeutics ranks #10 out of 332 companies in the Biotechnology industry, placing it in the top 3%.
Is CARISMA Therapeutics' EV-to-FCF too high?
CARISMA Therapeutics' current EV-to-FCF is 0.08. The Biotechnology industry median EV-to-FCF is 16.26. CARISMA Therapeutics' value of 0.08 is 99.5% below this industry median. Based on the distribution chart, CARISMA Therapeutics ranks #10 out of 332 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers.
How does CARISMA Therapeutics' EV-to-FCF compare to SCPX and CYTOF?
According to the Biotechnology industry distribution chart, CARISMA Therapeutics ranks #10 out of 332 companies for EV-to-FCF. This places CARISMA Therapeutics in the top 3% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 16.26. CARISMA Therapeutics' value of 0.08 is 99.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 16.26, based on 332 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CARISMA Therapeutics's current EV-to-FCF of 0.08 is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CARISMA Therapeutics and its competitors. For the Biotechnology industry, the median EV-to-FCF is 16.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CARISMA Therapeutics's current EV-to-FCF is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CARISMA Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CARISMA Therapeutics (CARM) is currently considered Possible Value Trap. The stock's GF Value™ is $3.71, compared to a current price of $0.01 — trading 99.8% below its estimated fair value. The current EV-to-FCF is 0.08 and 99.5% below the Biotechnology industry median of 16.26. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For CARISMA Therapeutics (CARM), the current EV-to-FCF is 0.08 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
CARISMA Therapeutics Inc is a clinical-stage cell therapy company focused on utilizing Carisma's proprietary chimeric antigen receptor macrophage and monocyte cell engineering platform to develop transformative immunotherapies to treat cancer and other serious diseases. The company has created a comprehensive cell therapy platform to enable the therapeutic use of engineered macrophages and monocytes, which belong to a subgroup of white blood cells called myeloid cells.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CARM has been successfully added to your 